Evolutionary Strategies in Acute Myeloid Leukemia

Evolutionary Strategies in Acute Myeloid Leukemia

How Genetics and Genomics Inform Therapeutic Decisions

Not a member of My prIME? Join now for instant access.

Meeting Overview

During this live symposium, experts will discuss new and evolving strategies available for patients with acute myeloid leukemia (AML). Tailoring treatment based on patient fitness, disease characteristics, and treatment goals is necessary for optimal outcomes. With several new agents in late-stage development, this symposium will review their efficacy and safety data and how to incorporate these agents into your clinical practice. Topics will include de novo, secondary, and relapsed/refractory AML. Clinical case scenarios will be presented and examined to learn from the experts.

A prIME Oncology satellite symposium to be held at the 23rd Congress of the European Hematology Association.

Date and Location

Thursday, 14 June 2018
08.00 – 10.00

Room: K1
Mässvägen 1
Älvsjö, Sweden



Thursday, 14 June 2018
08.00 – 10.00



Älvsjö, Sweden



2.0 AMA PRA Category 1 Credits

08.00 Welcome and introduction
Jorge Cortes, MD
08.03 Do you think like the experts?
Jorge Cortes, MD
08.08 Drilling down on the genomic landscape of AML
Adriano Venditti, MD
08.23 Q & A
08.28 Initial therapy for patients with de novo AML
Bob Löwenberg, MD, PhD
08.48 Q & A
08.53 Initial therapy for patients with secondary AML
Jorge Cortes, MD
09.08 Q & A
09.13 Strategies for relapsed/refractory AML
Nigel Russell, MD
09.28 Q & A
09.33 Evolving future strategies: A faculty panel discussion
Faculty Panel
09.48 Q & A
09.53 Repeat of “Do you think like the experts?”
Jorge Cortes, MD
09.58 Closing remarks
Jorge Cortes, MD
10.00 Adjourn


  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Faculty

  • Bob Löwenberg, MD, PhDErasmus University Medical Center
    Rotterdam, the Netherlands
  • Nigel Russell, MDNottingham University Hospitals NHS Trust
    Nottingham, United Kingdom
  • Adriano Venditti, MDUniversity of Rome "Tor Vergata"
    Rome, Italy

This educational activity is specifically designed to meet the needs of hematologists, oncologists, and other healthcare professionals involved in the management of patients with AML.

After successful completion of this educational activity, participants should be able to:

  • Develop treatment strategies for patients with AML using standard therapies as well as new/emerging agents
  • Differentiate the factors that impact treatment choice among de novo, secondary, and relapsed/refractory AML
  • Discuss efficacy and safety data of new/emerging treatment options that may be useful for patients with AML, and determine how these agents may best fit into treatment plans

This activity is supported by an educational grant from Jazz Pharmaceuticals.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Evolutionary Strategies in Acute Myeloid Leukemia - prIME OncologyprIME Oncology designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.